Radioprotection in mice following oral delivery of amifostine nanoparticles

References

• Andreassen CN, Grau C, Lindegaard JC. 2003. Chemical radioprotection: a critical review of amifostine as a cytopro-tector in radiotherapy. Sem Radiat Oncol 13(1):62–72.
   PubMed Web of Science ®Google Scholar
• Bonner HS, Shaw LM. 2002. New dosing regimens for amifos-tine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol 42:166–174.
   PubMed Web of Science ®Google Scholar
• Bukowski RM. 1996. Amifostine (Ethyol): dosing, administration, and patient management guidelines. Eur J Cancer 32\(Suppl. 4):S46–S49.
   Google Scholar
• Cassatt DR, Fazenbaker CA, Bachy CM, Hanson MS. 2002. Preclinical modeling of improved amifostine (ethyol) use in radiation therapy. Sem Radiat Oncol 12:97–102.
   PubMed Web of Science ®Google Scholar
• Cagnoni PJ, Jones RB, Bearman SI, Ross M, Hami L, Franklin WA, et al. 1996. Use of amifostine in bone marrow purging, Sem Oncol 23(Suppl. 8):44–48.
   Google Scholar
• Douay L. 1998. Negative selection and protection of normal progenitor cells for autografting. Bone Marrow Transplant 22(5):423–430.
   PubMedGoogle Scholar
• Fatome M, Courteille F, Laval JD, Roman V. 1987. Radio-protective activity of ethylcellulose microspheres containing WR 2721, after oral administration. Int J Radiat Biol Relat Stud Phys Chem Med 52:21–29.
   PubMed Web of Science ®Google Scholar
• Gogu SR, Beckman BS, Rangan SRS, Agrawal KC. 1989. A significant increase in therapeutic efficacy of zidovudine in the presence of vitamin E. Biochem Biophys Res Comm 165(1):401–407.
   PubMed Web of Science ®Google Scholar
• Haigentz M Jr., Kim M, Sorich J, Lee J, Hochster H, MacApinlac M, et al. 2003. Phase 1 study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with ad-vanced solid malignancies. Anti-Cancer Drugs 14(4):321–326.
   PubMedGoogle Scholar
• Jatoi A. 2003. Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine? Sem Oncol 30(Suppl. 18):72–75.
   Google Scholar
• Koukourakis MI. 2002. Amifostine in clinical oncology: current use and future applications. Anti-Cancer Drugs 13(3):181–209.
   PubMed Web of Science ®Google Scholar
• Lamperti A, Ziskin MC, Bergey E, Gorlowski J, Sodicoff M. 1990. Transdermal absorption of radioprotectors in the rat using permeation-enhancing vehicles. Radiat Res 24:194–200.
   Google Scholar
• Linares LA, Echols D. 2003. Amifostine and external beam radiation therapy and/or high-dose rate brachytherapy in the treatment of localized prostate carcinoma: preliminary results of a phase II trial. Sem Oncol 30\(Suppl. 18):58–62.
   PubMedGoogle Scholar
• Menard C, Camphausen K, Muanza T, Sears-Crouse N, Smith S, Ben-Josef E, et al. 2003. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results. Sem Oncol 30\(Suppl 18):63–67.
   PubMedGoogle Scholar
• Pamujula S, Graves R, Freeman T, Srinivasan V, Bostanian LA, Kishore V, et al. 2004a. Oral delivery of spray dried PLGA/ amifostine nanoparticles. J Pharm Pharmacol 56(9):1119–1125.
   PubMed Web of Science ®Google Scholar
• Pamujula S, Graves R, Kishore V, Mandal TK. 2004b. Prepara-tion and in vitro characterization of amifostine biodegradable microcapsules. Eur J Pharmaceut Biopharmaceut 57:213–218.
   PubMed Web of Science ®Google Scholar
• Samuels MA, Chico IM, Hirsch RL,, Fullmer K. 2003. Ethyol SQ Safety Study Group. Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design. Sem Oncol 30\(Suppl. 18):94–95.
   Google Scholar
• Schuchter LM, Hensley ML, Meropol NJ, Winer EP, 2002. Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American society of clinical oncology. J Chin Oncol 20:2895–2903.
   PubMed Web of Science ®Google Scholar
• Small W Jr. 2003. Radiation Therapy Oncology Group C-0116 trial. Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the Radiation Therapy Oncology Group C-0116 trial. Sem Oncol 30\(Suppl. 18):68–71.
   Google Scholar
• Srinivasan V, Pendergrass JA, Kumar KS, Landauer, Seed TM. 2002. Radioprotection, pharmacokinetic and behavioral stu-dies in mouse implanted with biodegradable drug (amifostine) pellets. Int J Radiat Biol 78:535–543.
   PubMed Web of Science ®Google Scholar
• Thorstad WL, Haughey B, Chao KS. 2003. Pilot of study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data. Sem Oncol 30\(Suppl 18):96–100.
   PubMedGoogle Scholar
• Withers HR, Elkind MM. 1970. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol 17:261–267.
   Web of Science ®Google Scholar